Il-2 mutations and pharmaceuticals containing these mutations

Abstract

The invention reveals IL-2 mutants and their uses. More specifically, the invention proposes IL-2 mutants and their corresponding fusion proteins, conjugates, nucleic acid fragments, vectors, corresponding host cells, methods for preparing mutants or fusion proteins, IL-2 mutants or fusion proteins prepared by such methods, pharmaceuticals, pharmaceutical uses, therapeutic methods, and methods for preferentially stimulating regulatory T cells. Compared to wild-type IL-2, the IL-2 mutant in the invention has a higher Tm value and improved stability; otherwise, the IL-2 mutant in the invention has increased yield or altered binding activity to the IL-2R£y complex compared to wild-type IL-2.